A&M STABTEST Labor für Analytik und Stabilitätsprüfung GmbH was established in 1995 by Dr Donald N. Dill, Dr Hans J. Diehl, Dr Hartmut Fischer and Dr Axel Römer as a spin-off from A&M Labor für Analytik und Metabolismusforschung GmbH. All founders are scientists with decades of experience in drug development. It is thanks to them, a corporate culture was installed, in which result-oriented work for our customers and quality are the top priorities. This approach has made us one of the largest GMP service providers for pharmaceutical analytics in Europe in recent decades. Since our foundation, we have been constantly adapting our GMP system to current regulatory requirements. The success of these efforts is regularly confirmed by GMP certifications and, since 2001, by inspections conducted by the US-FDA.

Our pronounced sense of quality and integrity is not only appreciated by regulatory authorities, but is also shared with our clients. This is why we have been providing or services to many of them since our founding years.

Working in continuous dialogue with our customers, we develop and expand our services in order to continue to be perceived as a competent partner in the innovative environment of pharmaceutical research. Within our organisation we work in specialized groups; for the storage and logistics of test items, the analysis of small molecules or proteins, mass spectrometry, the performance of bioassays or analytical development. All in order to satisfy the high quality requirements of our clients and international regulatory authorities.

We are proud, that we are currently Central Europe’s largest provider in the field of pharmaceutical analysis. And to ensure, that this remains the case, we not only continuously invest in modern analytical equipment and technologies, and in the continuous training and education of our employees, we also maintain a constant dialogue with our customers regarding future innovations in pharmaceutical research and development. For example, over 20 years ago we successfully supported the transformation of the pharmaceutical industry from chemically synthesised to biotechnologically produced active ingredients, and together with our innovative partners we are now developing analytical solutions for the next generation of cell- and gene-therapies.